Canaccord analyst Edward Nash lowered the firm’s price target on Morphic to $66 from $68 and keeps a Buy rating on the shares. The firm said they updated their estimated potential FDA approval and commercial launch time frame of MORF-057 in UC from 2027 to 2029, as well as a one-year pushback in the launch for UC in the EU.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MORF: